| DC22948 |
RU-TRAAK-2
Featured
|
RU-TRAAK-2 is a completely reversible TRAAK inhibitor, shows no activity for non-K2P channels (Kv1.2, Slo1 and GIRK2). |
|
| DC20938 |
Glufosfamide |
A conjugate of glucose and active alkylating moiety of ifosfamide with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters. |
|
| DC23256 |
Vipirinin |
A coumarin-based HIV-1 viral protein R (Vpr) inhibitor, inhibits Vpr-dependent viral infection of human macrophages. |
|
| DC23260 |
NPD4456
Featured
|
A coumarin-based HIV-1 viral protein R (Vpr) inhibitor, inhibits Vpr-dependent viral infection of human macrophages.. |
|
| DC23746 |
Chicago Sky Blue 6B |
A counterstain for background autofluorescence in fluorescence and immunofluorescence histochemistry, also is the first small molecule prion protein (PrP) ligand capable of inhibiting Aβ binding. |
|
| DC22569 |
BTTAA
Featured
|
BTTAA is a Cu(I)-stabilizing ligand, whch performs potently with ubiquitin Glu18AzF. |
|
| DCAPI1567 |
Lornoxicam |
A cyclooxygenase inhibitor. Structurally similar to Tenoxicam. An anti-inflammatory and an analgesic. |
|
| DC24151 |
Kinetin riboside |
A cytokinin analog that displays potent antiproliferative activity against various human cancer cell lines. |
|
| DC8540 |
DM-1(Mertansine)
Featured
|
A cytotoxic agent used in antibody-drug conjugates |
|
| DC24038 |
HQ-415 |
A derivative of 8-hydroxyquinoline that has selectivity for rescuing the distinct toxicities caused by the expression of TDP-43, α-synuclein or polyglutamine proteins. |
|
| DC22603 |
Dexrazoxane
Featured
|
A derivative of EDTA that chelates iron and reduces the number of metal ions complexed with anthracycline and, consequently, decrease the formation of superoxide radicals. |
|
| DC22999 |
CBR-096-4 |
A derivative of the antifungal drug itraconazole (ITA) as an inhibitor of MFB cell fate in resident fibroblasts derived from multiple murine and human tissues. |
|
| DC23228 |
(R)-Baclofen hydrochloride
Featured
|
A derivative of the neurotransmitter GABA that acts as a GABAB receptor agonist. |
|
| DC24088 |
Mutated EGFR-IN-1(Osimertinib analog)
Featured
|
A des acryl analogue of AZD9291 that is a useful intermediate for the inhibitors design for mutated EGFR, such as L858R EGFR, Exonl9 deletion activating mutant and T790M resistance mutant.. |
|
| DC22568 |
Taranabant (1R,2R) stereoisomer |
A diastereomer form of Taranabant, which is a potent, selective and orally active cannabinoid-1 receptor (CB1R) inverse agonist. |
|
| DC22829 |
Negamycin |
A dipeptide antibiotic that inhibits the initiation of protein synthesis. |
|
| DC24062 |
Nelociguat |
A direct soluble guanylate cyclase (sGC) stimulator that acts independently of nitric oxide (NO). |
|
| DC11538 |
AD-35 |
A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates. |
|
| DC11539 |
AD-35 hydrochloride |
A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates. |
|
| DC11537 |
AD-35 phosphate |
A donepezil analog that can moderately inhibit acetylcholinesterase and metal-induced Aβ aggregation in vitro and shows disassembly of Aβ aggregates. |
|
| DC11932 |
GPX-150 |
A doxorubicin analog that demonstrates anti-cancer activity without cardiotoxicity, does not inhibit topoisomerase IIβ activity at 100 uM. |
|
| DC24035 |
PROTO-1 |
A drug-like small molecule that prevents aminoglycoside-induced hair cell death in zebrafish and in mammals.. |
|
| DC22503 |
Val-Cit-PAB-MMAE
Featured
|
A drug-linker conjugate for Antibody-drug conjugates (ADCs) by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide Val-Cit-PAB.. |
|
| DC21858 |
Alchemix |
A dual action as an alkylating agent and topoisomerase inhibitor with potent activity against anthracycline- and cisplatin-resistant tumor cancer. |
|
| DC22889 |
AH-23848 calcium salt |
A dual antagonist of TP1 and EP4 receptors that inhibit TXA2-induced platelet aggregation with IC50 of 0.26 uM. |
|
| DC21055 |
GMI-1257 |
A dual inhibitor of E selectin and CXCR4 with IC50 of 3.6 uM and 1.1 uM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice. |
|
| DC21054 |
GMI-1215 |
A dual inhibitor of E selectin and CXCR4 with IC50 of 4.1 uM and 30 nM respectively, blocks adhesion of AML blasts to E-Selectin, mobilizes human AML engrafted in mice. |
|
| DC20391 |
Gingerenone A
Featured
|
Gingerenone A is a Nrf2-Gpx4 activator with anti-breast-cancer properties. Gingerenone A results a delayed G2/M in cancer cells, following oxidative stress and senescence responses. Gingerenone A also alleviates ferroptosis in secondary liver injury (SLI) in dextran sodium sulfate (DSS)-induced colitis mice. Gingerenone A can be isolated from Zingiber officinale. |
.gif)
|
| DC11708 |
Mitochonic Acid 35 |
A dual inhibitor of TNF-α and TGF-β1 by inhibiting IκB kinase phosphorylation and Smad3 phosphorylation. |
|
| DC24104 |
Almorexant
Featured
|
Almorexant(ACT078573) is a potent and competitive dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist with Ki values of 1.3 and 0.17 nM for OX1 and OX2, respectively.IC50 value: 1.3/0.7 nM(OX1/OX2 receptor) [1] [2]Target: Dual OX!/OX2 receptorin vitro: [(3)H]Almorexant bound to a single saturable site on hOX(1) and hOX(2) with high affinity (K(d) of 1.3 and 0.17 nM, respectively. In Schild analyses using the [(3)H]inositol phosphates assay, almorexant acted as a competitive antagonist at hOX(1) and as a noncompetitive-like antagonist at hOX(2). In binding kinetic analyses, [(3)H]almorexant had fast association and dissociation rates at hOX(1), whereas it had a fast association rate and a remarkably slow dissociation rate at hOX(2) [1]. in vivo: During the 12-h dark period after dosing, ALM(Almorexant) exacerbated cataplexy in TG mice and increased nonrapid eye movement sleep with heightened sleep/wake fragmentation in both genotypes. ALM showed greater hypnotic potency in WT mice than in TG mice. The 100 mg/kg dose conferred maximal promotion of cataplexy in TG mice and maximal promotion of REM sleep in WT mice. In TG mice, ALM (30 mg/ kg) paradoxically induced a transient increase in active wakefulness [3]. Almorexant 200 mg showed significantly less 'Drug Liking' than both zolpidem doses (p < 0.01), and almorexant 400 mg had smaller effects than zolpidem 20 mg (p < 0.05), while almorexant 1,000 mg was not different from either zolpidem dose [4]. |
|
